Methods to monitor and potentially modulate the systemic response to cancer, offer new avenues for early detection, personalized medicine and therapeutic modalities.

POC testing of penKid® and bio-ADM® is set to add significant clinical benefit to emergency departments and intensive care units allowing on-site diagnosis, monitoring, and guidance in therapies of sepsis, decongestion in heart failure and acute kidney injury, thereby improving outcomes in acute heart failure, sepsis and other acute settings.

The World Health Organization recommends IGRA tests in the First Edition of Essential In Vitro Diagnostics.

Ram Group aims to introduce revolutionary low-cost point-of-care diagnostics and healthcare monitoring devices to low-income communities.

Shuwen Biotech, a leading provider of innovative diagnostic products and medical diagnostic services, announced that studies based on its proprietary high-sensitivity CODAR-ARMS PCR liquid biopsy technology was selected to be published at the annual ASCO 2018.

Collaboration enables high yield, high purity supercoiled plasmid DNA manufacture for therapeutic application.

Complete and easy-to-use LC-MS-based solution for biotherapeutics characterization and quality testing.

Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announce that Unicancer, a hospital group entirely devoted to fighting cancer, has selected the MammaPrint® Breast Cancer Risk of Recurrence test and BluePrint® Molecular Subtyping test for use in its 18 French Comprehensive Cancer Centers (FCCC).

Daiichi Sankyo and Takeda Pharmaceuticals to leverage FDA-approved test for clinical trials and drug development programs.

Point-of-care test for detection of infection in patients on peritoneal dialysis available in France, Germany, Italy, The Netherlands, Austria and Switzerland.